Ease. Efficacy.





ENDOMETRIN® administered as a progesterone vaginal insert is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment for infertile women.

Important Safety Information

Only physicians thoroughly familiar with infertility treatment should prescribe ENDOMETRIN®. In clinical trials (n=808), adverse reactions that occurred at a rate greater than or equal to 2% included: uterine spasm (3% to 4%) and vaginal bleeding (3%). Vaginal irritation, itching, burning or discomfort, urticaria, and peripheral edema were reported at an incidence of less than 2%. ENDOMETRIN® is expected to have adverse reactions similar to other drugs containing progesterone (breast tenderness, bloating, mood swings, irritability, and drowsiness). ENDOMETRIN® is contraindicated in women who have or have had previous allergic reactions to progesterone or any of the ingredients in ENDOMETRIN®; a known missed abortion or ectopic pregnancy; liver disease; known or suspected breast cancer; active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.

Please go to www.ferringfertility.com and click on the ENDOMETRIN® logo to access Full Prescribing Information.

REFERENCES: 1. ENDOMETRIN [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals Inc; June 2007. **2.** Doody KJ, Schnell VL, Foulk RA, et al. Endometrin for luteal phase support in a randomized, controlled, open-label, prospective in-vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. *Fertil Steril*. 2009;91:1012-1017. **3.** Progesterone Supplementation: Evaluation of Attitudes and Satisfaction with Endometrin (EASE). Results of an Online Patient Survey. Parsippany, NJ: Ferring Pharmaceuticals Inc.; 2008. **4.** Data on file. Ferring Pharmaceuticals Inc.

